Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies Meeting Abstract
| Authors: | Drilon, A. E.; Dziadziuszko, R.; Camidge, D. R.; Lin, J. J.; Besse, B.; Kim, S. W.; Lee, K. H.; Solomon, B. J.; Nagasaka, M.; Goto, K.; Wolf, J.; De Langen, A. J.; Cheema, P. K.; Yang, N.; Velcheti, V.; Elamin, Y. Y.; Xu, Y.; Calvet, C.; Ades, F.; Cho, B. C. |
| Abstract Title: | Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557402020 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.8522 |
| Notes: | Meeting Abstract: 8522 -- Source: Wos |
